Business Context and Reporting Period
This Form 8-K Current Report was filed by ENDRA Life Sciences Inc. on December 27, 2019. The report addresses corporate governance and executive compensation matters rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the amendment of executive employment agreements.
Material Changes
On December 27, 2019, the Company entered into amendments to the employment letter agreements originally signed on May 12, 2017, with:
- Francois Michelon, President and Chief Executive Officer.
- Michael Thornton, Chief Technology Officer.
The amendments clarify that employment continues until terminated under the agreement terms and establish that both executives are eligible for specific payments if terminated without Cause or for Good Reason.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary disclosure relates to the terms of executive severance and termination provisions. The full text of the amendments is incorporated by reference as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Review Exhibit 10.1 and Exhibit 10.2 attached to this filing for the specific dollar amounts and conditions of the termination payments.
- Verify the definitions of "Cause" and "Good Reason" within the amended agreements to understand the triggers for severance.
- Check subsequent filings for any actual terminations or payments made under these new terms.